相关实验视频

Updated: Jun 28, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

破坏B细胞和T细胞在自身免疫性疾病中的协作:T细胞参与者与CAR T细胞治疗?

Kavina Shah¹, Maria Leandro^1,2, Mark Cragg³

¹Centre for Rheumatology, UCLH, London,UK.

Clinical and experimental immunology

|April 20, 2024

概括

新型T细胞疗法为克服自身免疫性疾病 (AID) 中B细胞枯竭抵抗提供了一个有希望的策略. 这些方法针对B细胞和T细胞的协作,解决当前治疗方法的局限性,如Rituximab.

科学领域:

免疫学免疫学免疫学
自免疫性疾病自免疫性疾病
治疗策略治疗策略

背景情况:

B和T细胞合作驱动自身免疫性疾病 (AID).
目前的治疗方法,如抗CD20单克隆抗体,可以实现B细胞枯竭 (BCD),但对于耐火性AID是不够的.
耐火性AID涉及B细胞群 (例如IgD-CD27+记忆B细胞,CD19+CD20-B细胞,血细胞) 和B-T细胞在炎症部位的协作,限制了BCD的疗效.

研究的目的:

讨论基于T细胞的新型治疗方法对耐火性AID的潜在机械优势.
探索T细胞效应器功能如何破坏B-T细胞协作并克服对现有疗法的抗性.

主要方法:

对艾滋病B细胞枯竭疗法的现有文献的审查.
在癌症治疗中对T细胞参与治疗方法 (例如,CAR T细胞疗法,T细胞参与剂) 的分析.
讨论这些基于T细胞的策略在耐火性AID等非瘤学指示中的潜在应用.

主要成果:

抗CD20疗法提供可变BCD,并且在耐火性AID中对某些B细胞种群无效.
通过招募T细胞来诱导B细胞细胞毒性,T细胞参与疗法在癌症中表现有前途.
有限的证据表明,抗CD19的CAR T细胞疗法可能对耐火性艾滋病有效.

结论:

利用T细胞作为效应细胞的新疗法有可能破坏B-T细胞协作.
这些以T细胞为基础的方法可以克服抗西马布抗性艾滋病.
进一步评估T细胞参与者对于耐火性AID等非瘤学迹象的进一步评估是有必要的.

关键词:

通过CAR T细胞疗法进行治疗.这些T细胞参与者.类风湿性关节炎类风湿性关节炎这就是Rituximab.系统性红血性狼 (Systemic Lupus Erythematosus) 是一种全身性狼.

更多相关视频

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...